PIK3CB and precursor B-cell acute lymphoblastic leukemia: The results allowed us to draw sound conclusions about the similarities and differences between both groups of patients and underlies once more the importance of the PI3K/Akt/mTOR pathway in B-ALL and points out specific cell cycle proteins as therapeutic targets for this pediatric malignancy.